Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Comprehensive long-term efficacy and safety of recombinant human alpha-mannosidase (velmanase alfa) treatment in patients with alpha-mannosidosis

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Correction to: Impact of age at onset and newborn screening on outcome in organic acidurias

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. A scoring system predicting the clinical course of CLPB defect based on the foetal and neonatal presentation of 31 patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Impact of age at onset and newborn screening on outcome in organic acidurias

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Age-related renal function decline in Fabry disease patients on enzyme replacement therapy: a longitudinal cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Impaired Fat Oxidation During Exercise in Long-Chain Acyl-CoA Dehydrogenase Deficiency Patients and Effect of IV-Glucose

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. l-Carnitine Improves Skeletal Muscle Fat Oxidation in Primary Carnitine Deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Osteogenesis imperfecta and the teeth, eyes, and ears-a study of non-skeletal phenotypes in adults

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Allan M Lund
  • Line Borgwardt
  • Federica Cattaneo
  • Diego Ardigò
  • Silvia Geraci
  • Mercedes Gil-Campos
  • Linda De Meirleir
  • Cécile Laroche
  • Philippe Dolhem
  • Duncan Cole
  • Anna Tylki-Szymanska
  • Monica Lopez-Rodriguez
  • Encarna Guillén-Navarro
  • Christine I Dali
  • Bénédicte Héron
  • Jens Fogh
  • Nicole Muschol
  • Dawn Phillips
  • J M Hannerieke Van den Hout
  • Simon A Jones
  • Yasmina Amraoui
  • Paul Harmatz
  • Nathalie Guffon
View graph of relations

INTRODUCTION: Long-term outcome data provide important insights into the clinical utility of enzyme replacement therapies. Such data are presented for velmanase alfa in the treatment of alpha-mannosidosis (AM).

METHODS: Patient data (n = 33; 14 adults, 19 paediatric) from the clinical development programme for velmanase alfa were integrated in this prospectively-designed analysis of long-term efficacy and safety. Patients who participated in the phase I/II or phase III trials and were continuing to receive treatment after completion of the trials were invited to participate in a comprehensive evaluation visit to assess long-term outcomes. Primary endpoints were changes in serum oligosaccharide and the 3-minute stair climb test (3MSCT).

RESULTS: Mean (SD) treatment exposure was 29.3 (15.2) months. Serum oligosaccharide levels were significantly reduced in the overall population at 12 months (mean change: -72.7%, P < 0.001) and remained statistically significant at last observation (-62.8%, P < 0.001). A mean improvement of +9.3% in 3MSCT was observed at 12 months (P = 0.013), which also remained statistically significant at last observation (+13.8%, P = 0.004), with a more pronounced improvement detected in the paediatric subgroup. No treatment-emergent adverse events were reported leading to permanent treatment discontinuation.

CONCLUSIONS: Patients treated with velmanase alfa experienced improvements in biochemical and functional measures that were maintained for up to 4 years. Long term follow-up is important and further supports the use of velmanase alfa as an effective and well-tolerated treatment for AM. Based on the currently available data set, no baseline characteristic can be predictive of treatment outcome. Early treatment during paediatric age showed better outcome in functional endpoints.

Original languageEnglish
JournalJournal of Inherited Metabolic Disease
Volume41
Issue number6
Pages (from-to)1225-1233
Number of pages9
ISSN0141-8955
DOIs
Publication statusPublished - Nov 2018

ID: 56311059